Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology

Follicular Lymphoma

California

La Jolla : Moores UCSD Cancer Center

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Lo Jolla : UCSD Moore´s Cancer Center

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Los Angeles : University of California LA (UCLA),Hematology Oncology Center

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

San Diego : Scripps Clinic

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Colorado

Aurora : University of Colorado Anschutz Cancer Center

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Illinois

Chicago : University of Chicago

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Chicago : Northwestern University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Chicago : Rush University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Chicago : Rush University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Iowa

Iowa City : University of Iowa Hospital and Clinics

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Massachusetts

Boston : Dana-Farber Cancer Institute

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Boston : Dana Farber Cancer Institute

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Michigan

Ann Arbor : University of Michigan

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Detroit : Barbara Ann Karmanos Cancer Institute

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

New Jersey

Hackensack : The Cancer Center of Hackensack University Medical Center

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

New York

Buffalo : Roswell Park Cancer Institute

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

North Carolina

Chapel Hill : University of North Carolina

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Durham : Duke University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Ohio

Cleveland : Case Western Reserve University Ireland Cancer Center

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Columbus : The Ohio State University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Oregon

Portland : Oregon Health & Science University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Portland : Oregon Health & Science University

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Pennsylvania

Philadelphia : Temple University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Pittsburgh : The University of Pittsburgh Medical Center (UPMC)

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

South Carolina

Greenville : Cancer Centers of the Carolinas

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Texas

Houston : University of Texas

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Houston : MD Anderson Cancer Center

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Argentina

Buenos Aires : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Mendoza : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Rosario : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Australia

Ashford : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Fitzroy : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Kogarah : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Sydney : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Brazil

Barretos : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Porto Alegre : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Sao Paulo : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Canada

Calgary, AB : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Halifax, NS : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Montreal, QC : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Ottawa, ON : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Czech Republic

Bmo : Faculty Hospital Brno

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Brno : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Hradec Kralove : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Hradec Kralove : Faculty Hospital Hradec Kralove

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Novy Jicin : Onkologicke centrum J.G. Mendela

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Prague : Faculty Hospital Kralovske Vinohrady

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Prague : General Faculty Hospital,

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Praha : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Denmark

Herlev : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Ecuador

Guayaquil : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Quito : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Finland

Helsinki : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Tampere : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Turku : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

France

Bayonne : Centre Hospitalier de la côte basque/Bayonne

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Brest : CHU BREST

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Caen : CHU Clémenceau

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Creteil : CHU Creteil

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Grenoble : CHU Michallon

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Limoges : CHU de Limoges

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Marseille : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Marseille : Institut Paouli Calmette

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Montpellier : CHU Montpellier/Lapeyronie

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Nantes : CHU Nantes

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Nice : CHU NICE

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Paris : CIC St Louis

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Pessac : CHU Bordeaux

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Pierre-Benite Cedex : Centre Hospitalier Lyon Sud

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Poitiers : Hopital Jean Bernard

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Reims : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Reims : Hopital Robert Debre

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Rennes : Centre Hospitalier et Universitaire

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Vandoeuvre-les-Nancy : Hopital d'adultes de Brabois

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Villejuif : Institut Gustave Roussy

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Germany

Essen : Uniklinik Essen

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Hamburg : Allgemeines Krankenhaus St. Georg

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Homburg/Saar : Universitätskliniken des Saarlande

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Kiel : Universitätsklinikum Schleswig-Holstein

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Mönchengladback-Rheydt : Practice for Hematology and Oncology, At the Elisabeth-Krankenhaus Rheydt

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Reims : Justus-Liebig-Universität

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Ulm : Universitätsklinikum Ulm

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Hungary

Budapest : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Debrecen : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Gyor : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Gyula : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Kaposvar : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Miskolc : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Nyíregyháza : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Pecs : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Szeged : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Székesfehérvár : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Szekszard : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Szolnok : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Szombathely : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Tatabánya : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Zalaegerszeg : Research Site:

A Study of Long-Term MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma

Israel

Haifa : Rambam Healthcare Campus

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Jerusalem : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Jerusalem : Hadassah Medical Organization

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Petach Tikva : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Ramat Gan : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Tel-Hashomer : Chaim Sheba Medical Center

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Italy

Bari : Università degli studi di Bari- Ospedale Policlinico

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Bergamo : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Bologna : Università degli studi di Bologna

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Milano : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Milano : Ospedale Niguarda Cà Granda

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Pisa : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Rozzano (MI) : Istituto Clinico Humanitas

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Torino : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Mexico

Aguascalientes : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Mexico City : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Monterrey : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Netherlands

Nijmegen : University Medical Centre Nijmegen

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Amersfoort : Meander Medical Center

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Amsterdam : University of Amsterdam

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Enschede : Medisch Spectrum Twente

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Groningen : University Medical Center Groningen

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Norway

Oslo : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Peru

Lima : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Poland

Gdansk : Klinika Hematologii AM

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Krakow : Klinika Hematologii CMUJ

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Lodz : Klinika Hematologii AM

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Lodz : Regionalne Centrum Onkologii

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Lublin : Centrum Onkologii Ziemi Lubelskiej

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Olszytyn : Regionalne Centrum Onkologii w Olszytynie Oddzial Chemioterapii

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Poznan : Klinika Hematologii CMUJ

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Siedlce : Wojewodzki Szpital Specjalistyczny

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Warszawa : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Warszawa : Onkologii i Chorob Wewnetrznych AM

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Warszawa : Instytut Hematologii i Transfuzjologii

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Warszawa : Klinika Nowotworow Ukladu Chlonnego

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Wrocalw : Klinika Hematologii AM

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Wroclaw : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Russian Federation

Moscow : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Slovakia

Bratislava : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Spain

Badalona : Hospital Germans Trias i Pujol

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Barcelona : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Barcelona : Hospital del Mar

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Barcelona : Hospital de la Santa

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Cadiz : Hospital Universitario Puerta del Mar

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Llobregat : L´Hospitalet del Llobregat

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Madrid : MD ANDERSON International

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Salamanca : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Sevilla : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Valencia : Hospital Universitario La Fe

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Sweden

Huddinge : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Lund : University Hospital in Lund

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Lund : University Hospital in Lund

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Sundsvall : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Sundsvall : Sundsvall Hospital

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Umea : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Uppsala : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Switzerland

Basel : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

United Kingdom

Aberdeen : Aberdeen Royal Infirmary

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Belfast : Belfast City Hospital

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Cardiff : Velindre Hospital

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Liverpool : Royal Liverpool University Hospital, Department of Haematology

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

London : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

London : St. George's Healthcare NHS Trust

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

London : University College Hospital

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Manchester : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Manchester : Christie Hospital NHS Trust

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Northwood, Middlesex : Mount Vernon Hospital

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Nottingham : Research Site:

A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

Plymouth : Derriford Hospital, Department of Haematology

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Southampton : Southampton General Hospital

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.

Worcester : Worcestershire Royal Hospital

If the patient has Follicular Lymphoma and is refractory to rituximab as monotherapy or in combination with chemotherapy or to rituximab as a maintenance treatment, he/she may be eligible for this clinical trial.